The drugs don't work for AstraZeneca

With its product cupboard looking increasingly bare, Britain's second-biggest drug maker may have to go shopping for growth

AstraZeneca has one dreadful headache, and nothing in its drug cabinet looks likely to make the pain go away. Yesterday, Britain's second-biggest drug maker admitted it would face a $380m (£242m) writedown this year after two of its major new drugs failed to hit targets in mid and late-stage clinical trials. The diminished prospects for its ovarian cancer drug olaparib and an experimental antidepressant named TC-5214 will, Astra admitted, damage expectations for its annual earnings, now forecast to come in at the lower end of its previous range of $7.20 to $7.40 per share.

Still, analysts had already whipped the antidepressant out of their models after its first trial failure last month, and the cancer drug was known to be high risk. So that blow was just a sniffle compared to Astra's real ailment: the pharma giant is suffering from a "patent cliff" that will see at least half of its drug sales face generic competition by 2016.

It's started already. Astra's $1.5bn-a-year cancer drug Arimidex faced generic competition for the first time last year. Blockbuster heartburn drug Nexium has already started competing with generics in Europe. It, together with Seroquel, Astra's best-selling bipolar drug, bought in combined revenues of $10.3bn last year: both will have generic competitors in the crucial, US market from 2014.

The coming months will also put Astra's cholesterol-buster Crestor, which bought in sales worth $5.7bn last year, under the spotlight. Lipitor, its Pfizer-made rival which is the world's bestselling medicine, has just come out of patent. The flood of cheap, generic alternatives is likely to hit Crestor's sales, leaving Astra with another revenue hole it needs to fill.

How will the gap be filled? There is no obvious source. Even before yesterday's double bad news, Astra's pipeline was thin. In February, it called off late-stage trials of a prostate cancer drug, zibotentan. A year ago, it wrote off $445m abandoning a new respiratory medicine for children, motavizumab.

"AstraZeneca has had two years of product failures. We're concerned," said Navid Malik, head of life science research at Merchant Securities. "The pipeline is devoid of late-stage potential blockbusters... Astra's more-established products are going generic, and the cupboard is beginning to look bare."

The drug maker has had one big success: blood thinner Brilinta launched in Europe (where it is sold as Brilique) at the end of last year, followed by the US a few months later. Analysts think it could hit sales of $1bn by 2015. But overall, despite success in emerging markets, the company's revenues are forecast to decline over the next five years.

So far, profits are holding up: in the third quarter of this year, revenues at constant currency declined 2 per cent thanks to patent expiries, but pre-tax profit was up, in part thanks to major cost-cutting [see box].

When Astra started to announce job cuts in 2008, it helped the City warm to the stocks. But this year the shine has come off. Despite more cost-cutting and the fact that drug stocks are considered a safe haven in a downturn, its shares are still down over the past year. Yesterday's news sent them lower again, off 44p to 2,905p.

The City is questioning where growth will come from next.

Its chief executive, David Brennan, almost certainly needs to go shopping, and City whispers suggest Dublin-headquartered tax exile Shire could be a target: it is expected to post double-digit revenue growth over the next few years thanks to its high-margin, highly specialised drugs.

"The business is growing very significantly," says Mr Malik. "An acquirer could take out a lot of its costs and drive revenue growth.

"Astra could be the one to do so. It needs to do something."

Bad medicine: Jobs go

This week AstraZeneca said it was axeing a quarter of its US sales staff – some 1,150 jobs – to further cut costs. That was a second wave of job losses as the drug maker, which employs 61,000 people around the world, continues its ambition to axe 10,400 jobs in the next three years. Doing so will, Astra says, save $1bn (£637m) a year. The UK has felt the pain of the job cuts too: Astra closed its research facility in Loughborough last year with the loss of 1,200 jobs. Meanwhile, it is expanding in emerging markets. In October, AstraZeneca set out plans to spend $200m in China, creating the most expensive factory it has ever built.

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
Ben Stiller as Derek Zoolander in the leaked trailer for Zoolander 2
film
Sport
footballArsenal take the Community Shield thanks to a sensational strike from Alex Oxlade-Chamberlain
Arts and Entertainment
Gemma Chan as synth Anita in Humans
film
News
Keeping it friendly: Tom Cruise on ‘The Daily Show’ with Jon Stewart
people
Arts and Entertainment
Ensemble cast: Jamie McCartney with ‘The Great Wall of Vagina’
artBritish artist Jamie McCartney explains a work that is designed to put women's minds at rest
News
Republican Presidential Candidate Donald Trump
people
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: DBA Developer - SQL Server

£30000 - £35000 per annum: Recruitment Genius: This is an exciting opportunity...

Recruitment Genius: Customer Service Administrator

£13000 - £15000 per annum: Recruitment Genius: Are you passionate about custom...

Recruitment Genius: Dialler Administrator

£22000 - £25000 per annum: Recruitment Genius: Main purpose: Under the directi...

Ashdown Group: Contracts Manager - City of London

£35000 - £37000 per annum + benefits : Ashdown Group: Contracts Manager - City...

Day In a Page

Turkey-Kurdish conflict: Obama's deal with Ankara is a betrayal of Syrian Kurds and may not even weaken Isis

US betrayal of old ally brings limited reward

Since the accord, the Turks have only waged war on Kurds while no US bomber has used Incirlik airbase, says Patrick Cockburn
VIPs gather for opening of second Suez Canal - but doubts linger over security

'A gift from Egypt to the rest of the world'

VIPs gather for opening of second Suez Canal - but is it really needed?
Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

Jeremy Corbyn dresses abysmally. That's a great thing because it's genuine

Fashion editor, Alexander Fury, applauds a man who clearly has more important things on his mind
The male menopause and intimations of mortality

Aches, pains and an inkling of mortality

So the male menopause is real, they say, but what would the Victorians, 'old' at 30, think of that, asks DJ Taylor
Man Booker Prize 2015: Anna Smaill - How can I possibly be on the list with these writers I have idolised?

'How can I possibly be on the list with these writers I have idolised?'

Man Booker Prize nominee Anna Smaill on the rise of Kiwi lit
Bettany Hughes interview: The historian on how Socrates would have solved Greece's problems

Bettany Hughes interview

The historian on how Socrates would have solved Greece's problems
Art of the state: Pyongyang propaganda posters to be exhibited in China

Art of the state

Pyongyang propaganda posters to be exhibited in China
Mildreds and Vanilla Black have given vegetarian food a makeover in new cookbooks

Vegetarian food gets a makeover

Long-time vegetarian Holly Williams tries to recreate some of the inventive recipes in Mildreds and Vanilla Black's new cookbooks
The haunting of Shirley Jackson: Was the gothic author's life really as bleak as her fiction?

The haunting of Shirley Jackson

Was the gothic author's life really as bleak as her fiction?
Bill Granger recipes: Heading off on holiday? Try out our chef's seaside-inspired dishes...

Bill Granger's seaside-inspired recipes

These dishes are so easy to make, our chef is almost embarrassed to call them recipes
Ashes 2015: Tourists are limp, leaderless and distinctly UnAustralian

Tourists are limp, leaderless and distinctly UnAustralian

A woefully out-of-form Michael Clarke embodies his team's fragile Ashes campaign, says Michael Calvin
Blairites be warned, this could be the moment Labour turns into Syriza

Andrew Grice: Inside Westminster

Blairites be warned, this could be the moment Labour turns into Syriza
HMS Victory: The mystery of Britain's worst naval disaster is finally solved - 271 years later

The mystery of Britain's worst naval disaster is finally solved - 271 years later

Exclusive: David Keys reveals the research that finally explains why HMS Victory went down with the loss of 1,100 lives
Survivors of the Nagasaki atomic bomb attack: Japan must not abandon its post-war pacifism

'I saw people so injured you couldn't tell if they were dead or alive'

Nagasaki survivors on why Japan must not abandon its post-war pacifism
Jon Stewart: The voice of Democrats who felt Obama had failed to deliver on his 'Yes We Can' slogan, and the voter he tried hardest to keep onside

The voter Obama tried hardest to keep onside

Outgoing The Daily Show host, Jon Stewart, became the voice of Democrats who felt the President had failed to deliver on his ‘Yes We Can’ slogan. Tim Walker charts the ups and downs of their 10-year relationship on screen